{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015947","form_type":"8-K","ticker":null,"cik":"0001783032","company_name":"Elevation Oncology, Inc.","filed_at":"2023-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.215234+00:00","generated_at":"2026-06-10T09:47:46.010488+00:00","sec_items":["3.01","5.02"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elevation Oncology receives Nasdaq bid-price deficiency notice; director resigns","bullets":["Nasdaq notified on Sep 19, 2023 that bid price below $1.00 for 30 consecutive days; company has until Mar 18, 2024 to regain compliance.","To cure, closing bid must be at least $1.00 for 10 consecutive business days by Mar 18, 2024.","Director Colin Walsh resigned effective Sep 21, 2023 citing other professional opportunities; no disagreement with company.","Steven A. Elms appointed to fill Audit Committee vacancy left by Walsh's resignation.","Company considering actions to regain compliance; no assurance of success or continued listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015947","json":"https://secwatch.observer/filing/0001558370-23-015947.json","markdown":"https://secwatch.observer/filing/0001558370-23-015947.md","text":"https://secwatch.observer/filing/0001558370-23-015947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/0001558370-23-015947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/elev-20230919x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:47:46.010488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b560c9061c96a9fe960e2e7193583c16903f30be","claim":"Elevation Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"September 19, 2023, Elevation Oncology, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. Pursuant to N","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/0001558370-23-015947-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"3086fe730e","claim":"Colin Walsh resigned as Director at Elevation Oncology, Inc..","evidence_excerpt":"On September 21, 2023, Colin Walsh, Ph.D., notified the Company of his resignation from the Board of Directors of the Company (the \"Board\"), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783032/000155837023015947/0001558370-23-015947-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}